iRadimed/$IRMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About iRadimed
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
- Ticker
- $IRMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 166
- Headquarters
- Orlando, United States
- Website
- www.iradimed.com
iRadimed Metrics
BasicAdvanced
$1.1B
46.89
$1.79
0.90
$1.27
0.95%
Price and volume
Market cap
$1.1B
Beta
0.9
52-week high
$107.90
52-week low
$75.75
Average daily volume
124K
Dividend rate
$1.27
Financial strength
Current ratio
9.463
Quick ratio
7.887
Dividend payout ratio (TTM)
68.66%
Profitability
EBITDA (TTM)
29.184
Gross margin (TTM)
75.86%
Net profit margin (TTM)
26.70%
Operating margin (TTM)
31.92%
Effective tax rate (TTM)
22.49%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
15.56%
Return on equity (TTM)
23.52%
Valuation
Price to earnings (TTM)
46.893
Price to revenue (TTM)
12.4
Price to book
10.55
Price to tangible book (TTM)
10.92
Price to free cash flow (TTM)
43.617
Free cash flow yield (TTM)
2.29%
Free cash flow per share (TTM)
1.924
Dividend yield (TTM)
1.51%
Forward dividend yield
0.95%
Growth
Revenue change (TTM)
11.21%
Earnings per share change (TTM)
11.18%
3-year revenue growth (CAGR)
12.98%
10-year revenue growth (CAGR)
9.31%
3-year earnings per share growth (CAGR)
15.31%
10-year earnings per share growth (CAGR)
9.90%
What the Analysts think about iRadimed
Analyst ratings (Buy, Hold, Sell) for iRadimed stock.
Analyst projections of the future price of iRadimed stock.
Bulls say / Bears say
Bookings for the new 3870 pump were more than twice the number shipped in Q2, suggesting demand is building ahead of the product’s wider rollout. (The Motley Fool)
More than 70% of new pump orders were for four-pump configurations, which management said can lift average selling prices by over 20%. That could make the installed-base replacement cycle more valuable than a like-for-like upgrade. (The Motley Fool)
There are signs of strength beyond the pump launch: domestic patient-monitor bookings hit a record in Q2, while disposable revenue rose 14% year on year. This gives the growth story support from monitoring and recurring consumables as well as pumps. (iRadimed)
Q2 revenue grew just 0.5% year on year, while diluted EPS fell 9%. The new pump transition has yet to translate into stronger reported growth. (iRadimed)
Gross margin fell to 74% from 78% in Q2 2025 as the first substantial 3870 production ramp brought higher costs and inefficiencies. A slower-than-planned improvement in manufacturing efficiency could weigh on earnings. (iRadimed)
Needham initiated coverage with a Hold, arguing that the shares’ valuation already reflects much of the growth opportunity. That leaves less room for disappointment if the 3870 rollout or replacement cycle falls short. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
iRadimed Financial Performance
Revenues and expenses
iRadimed Earnings Performance
Company profitability
Upcoming events
No upcoming events
iRadimed News
AllArticlesVideos
Funds containing iRadimed
Fund name | Fund size | $IRMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.00% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.